MindSpire Secures £850K to Enhance Stress Management
Revolutionizing Stress Management: MindSpire Secures £850K in Funding
In an exciting development for the neurotech landscape, MindSpire has successfully raised £850,000 in pre-seed funding, a significant boost that will propel the launch of its innovative AI-powered wearable device, SONA™. This funding round was spearheaded by SFC Capital, with notable participation from SyndicateRoom and additional non-dilutive innovation funds from Innovate UK’s Investor Partnership Programme. With this investment, MindSpire, located at the London Institute for Healthcare Engineering (LIHE), is set to bridge the gap in real-time stress regulation through cutting-edge technology.
The SONA™ device is more than just a wearable; it represents a new frontier in managing chronic stress and enhancing overall mental health.
By employing precision-coded electrical pulses that target the vagus nerve, SONA™ activates specific brain circuits, offering users a tailored approach to achieving calm, focus, and improved cognitive function. As the founder and CEO, Jane Ollis, emphasized, this groundbreaking technology is designed to assist not only high-performing executives but also individuals dealing with anxiety, long COVID, trauma, and burnout, ensuring that effective nervous system care is accessible to all.
Moreover, the potential synergy between AI and neuroscience in MindSpire's approach excites investors like Dr. Amir Konigsberg, who sees a transformative opportunity in providing personalized, real-time interventions. As MindSpire continues to build strategic partnerships and prepare for future funding rounds, they aim to further develop their technology while actively engaging investors who share their vision for a healthier, more resilient society. To stay connected with MindSpire and explore partnership opportunities, visit their LinkedIn page and join the movement aiming to make stress regulation universally accessible.
Key Terms Explained
- Pre-seed funding
- This is the first of institutional funding stages and typically the starting point of any business. The funding helps the startup to cover initial operating expenses and to move from being a mere idea to the prototype phase.
- Non-dilutive innovation funds
- These are types of financing that don't require the sale of your company's shares, hence it doesn't dilute the ownership of the company's original stakeholders. It's often in the form of grants, and in this context provided by Innovate UK’s Investor Partnership Programme.
- Strategic Partnerships
- A mutually beneficial arrangement between two businesses in which each brings something to the table that benefits the other. MindSpire aims to build these collaborations to strengthen and develop their technology.
Frequently Asked Questions
- How much funding did MindSpire secure in its pre-seed round?-MindSpire secured £850,000 in its pre-seed funding round.
- Who led the funding round for MindSpire?+
- What is the purpose of the funding received by MindSpire?+
- Who are the potential users of the SONA™ device?+
- What is the vision that MindSpire's investors share?+
They've invested in MindSpire
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK